organonbiosim Profile Banner
Organon Biosimilars Profile
Organon Biosimilars

@organonbiosim

Followers
495
Following
6
Media
62
Statuses
79

Organon is committed to supporting the adoption of biosimilars across the health care system. U.S. residents only. https://t.co/LTtVttM50l

Jersey City, NJ, USA
Joined October 2020
Don't wanna be here? Send us removal request.
@organonbiosim
Organon Biosimilars
2 years
At Organon, we are committed to listening, learning, and sharing knowledge to help realize biosimilar goals. #biosimilars
0
0
2
@organonbiosim
Organon Biosimilars
3 years
Jim Carey, Head of US Policy and Government Relations, speaks to one of our core partnerships: The Biosimilars Forum.
0
3
9
@organonbiosim
Organon Biosimilars
3 years
#Biosimilars are designed to be highly similar to biologic medicine and have no clinically meaningful difference. Learn more about the basics of biosimilars here:
0
1
6
@organonbiosim
Organon Biosimilars
3 years
We are looking forward to seeing how the Biologics Price Competition and Innovation Act (BPCIA) continues to foster #biosimilars growth. #BPCIA
0
1
5
@organonbiosim
Organon Biosimilars
3 years
#DYK that in 2021, brand #biologics and specialty medicines represented only 3% of all U.S. prescriptions, but accounted for 55% of net drug spending?
0
1
7
@organonbiosim
Organon Biosimilars
3 years
The correct answer is 90% of physicians! Those surveyed also shared they have a high level of confidence in the FDA-approval process for biosimilars. Learn more about the survey here:
@organonbiosim
Organon Biosimilars
3 years
In 2021, 500 US physicians participated in a survey around #biosimilars. What percentage of physicians believed that biosimilars have similar effectiveness and safety to the reference brand?
0
0
4
@organonbiosim
Organon Biosimilars
3 years
In 2021, 500 US physicians participated in a survey around #biosimilars. What percentage of physicians believed that biosimilars have similar effectiveness and safety to the reference brand?
0
1
2
@organonbiosim
Organon Biosimilars
3 years
Through commitment, passion, education, and innovation - we look forward to realizing the potential of biosimilars together.
0
2
10
@organonbiosim
Organon Biosimilars
3 years
Cheers to 2023! What are you looking forward to in the biosimilars space this year?
0
1
7
@organonbiosim
Organon Biosimilars
3 years
Learn about the rigorous approval standards for #biosimilars required by the FDA through the #BiosimilarsForum
@USBiosimilars
Biosimilars Forum
3 years
#Biosimilars must meet the same product and manufacturing quality standards as any FDA-licensed biologic medicine. Learn the #biosimilar basics from our website here:
0
1
4
@organonbiosim
Organon Biosimilars
3 years
As #biosimilars become a bigger part of our healthcare landscape, the @US_FDA has laid out a multifaceted action plan to foster biologic innovation and development.
0
1
2
@organonbiosim
Organon Biosimilars
3 years
What #generics were to the US healthcare system in the 20th century is what #biosimilars have the potential to become in the 21st century.
0
1
3
@organonbiosim
Organon Biosimilars
3 years
Opportunities. Insights. Possibilities. Our own Joe Azzinaro recently shared Organon's important next moves in the ever-evolving world of healthcare. #profile #biosimilars
0
1
3
@organonbiosim
Organon Biosimilars
3 years
Everything is bigger in Texas, including the largest scientific gathering in breast cancer research. Register now for the San Antonio Breast Cancer Symposium (SABCS) from Dec. 6-10. Come see us at booth #729! #biosimilars
0
1
3
@organonbiosim
Organon Biosimilars
3 years
Transitioning patients to #biosimilars comes with many questions. We’re here to clear things up.
0
0
4
@organonbiosim
Organon Biosimilars
3 years
Our goal is to help you feel confident while navigating the biosimilar implementation process. You can learn more here https://t.co/YWXvhJiga3 #biosimilars
0
0
5
@organonbiosim
Organon Biosimilars
3 years
As #GlobalBiosimilarsWeek comes to a close, we hope you’ll carry today’s theme forward by joining the biosimilars movement to continue the conversation and help advance the adoption of #biosimilar medicines. #GBW22
0
0
4
@organonbiosim
Organon Biosimilars
3 years
Biosimilars undergo testing to determine there are no clinically meaningful differences in safety, purity, and effectiveness compared to the reference biologic before they are approved for use. Join the conversation using #GlobalBiosimilarsWeek #GBW22
0
0
8
@organonbiosim
Organon Biosimilars
3 years
By increasing competition in the market, #biosimilars have the potential to save the US more than $100 billion between 2020 and 2024. Join the conversation during #GlobalBiosimilarsWeek https://t.co/XI4OMwoWV4 #GBW22
2
1
13
@organonbiosim
Organon Biosimilars
3 years
#Biosimilars undergo a rigorous approval process demonstrating no clinically meaningful differences to the reference product and may provide access to additional treatment options. #GlobalBiosimilarsWeek #GBW22
0
0
9